piracetam has been researched along with Mental Disorders in 30 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5-year period was performed at the Columbia Comprehensive Epilepsy Center to identify children who were treated with levetiracetam doses titrated above the usual 40-60mg/kg/day." | 7.76 | Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. ( Obeid, M; Pong, AW, 2010) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 7.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 6.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| "Levetiracetam is a new anticonvulsant (AED) with a novel mechanism of action." | 5.31 | Levetiracetam psychosis in children with epilepsy. ( Bergey, GK; Freeman, JM; Kossoff, EH; Vining, EP, 2001) |
| "5-year period was performed at the Columbia Comprehensive Epilepsy Center to identify children who were treated with levetiracetam doses titrated above the usual 40-60mg/kg/day." | 3.76 | Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy. ( Obeid, M; Pong, AW, 2010) |
| " Three regulatory trials have demonstrated that add-on levetiracetam is efficacious in patients with localization-related epilepsy." | 3.74 | Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Diepman, L; Gehring, J; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Ricker, L; Schellekens, A, 2007) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "Levetiracetam was discontinued in 4." | 2.53 | Safety of Levetiracetam in Paediatrics: A Systematic Review. ( Choonara, I; Egunsola, O; Sammons, HM, 2016) |
| "Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders." | 2.45 | Levetiracetam for managing neurologic and psychiatric disorders. ( Bhatt, A; Farooq, MU; Gupta, R; Kassab, MY; Khasnis, A; Majid, A, 2009) |
| " In Phase II/III trials, the adverse effects occurring more commonly in the treatment groups versus the placebo group were; somnolence (14." | 2.42 | Levetiracetam safety profiles and tolerability in epilepsy patients. ( Briggs, DE; French, JA, 2004) |
| " Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause." | 1.46 | Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. ( Belcastro, V; Bellocchi, S; Casiraghi, P; Gorgone, G; Mula, M; Pisani, F; Pisani, LR, 2017) |
| " Following adjunctive AED treatment, neuropsychiatric adverse effects led to AED withdrawal in 1." | 1.46 | Psychiatric side effects and antiepileptic drugs: Observations from prospective audits. ( Brodie, MJ; Stephen, LJ; Wishart, A, 2017) |
| "To investigate the hypothesis that some patients with epilepsy are generally prone to develop psychiatric adverse events (PAEs) during antiepileptic drug (AED) therapy irrespective of the mechanism of action of the drugs." | 1.34 | Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. ( Mula, M; Sander, JW; Trimble, MR, 2007) |
| "Levetiracetam is a new anticonvulsant (AED) with a novel mechanism of action." | 1.31 | Levetiracetam psychosis in children with epilepsy. ( Bergey, GK; Freeman, JM; Kossoff, EH; Vining, EP, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (23.33) | 18.7374 |
| 1990's | 2 (6.67) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Davis-Reyes, BD | 1 |
| Smith, AE | 1 |
| Xu, J | 1 |
| Cunningham, KA | 1 |
| Zhou, J | 1 |
| Anastasio, NC | 1 |
| Belcastro, V | 1 |
| Pisani, LR | 1 |
| Bellocchi, S | 1 |
| Casiraghi, P | 1 |
| Gorgone, G | 1 |
| Mula, M | 2 |
| Pisani, F | 1 |
| Stephen, LJ | 1 |
| Wishart, A | 1 |
| Brodie, MJ | 2 |
| McKee, KE | 1 |
| Etherton, MR | 1 |
| Lovitch, SB | 1 |
| Gupta, AS | 1 |
| Micalizzi, DS | 1 |
| Tierney, T | 1 |
| Wadleigh, M | 1 |
| Vaitkevicus, H | 1 |
| Yates, SL | 1 |
| Fakhoury, T | 1 |
| Liang, W | 1 |
| Eckhardt, K | 1 |
| Borghs, S | 1 |
| D'Souza, J | 1 |
| Chowdhury, A | 1 |
| Egunsola, O | 1 |
| Choonara, I | 1 |
| Sammons, HM | 1 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Farooq, MU | 1 |
| Bhatt, A | 1 |
| Majid, A | 1 |
| Gupta, R | 1 |
| Khasnis, A | 1 |
| Kassab, MY | 1 |
| Obeid, M | 1 |
| Pong, AW | 1 |
| Mataam, K | 1 |
| Ilboudo, JC | 1 |
| Gazaigne, L | 1 |
| Wafo, E | 1 |
| Angenard, F | 1 |
| Goodman, MJ | 1 |
| Durkin, M | 1 |
| Forlenza, J | 1 |
| Ye, X | 1 |
| Brixner, DI | 1 |
| Cramer, JA | 1 |
| Van Hammée, G | 1 |
| Brodtkorb, E | 1 |
| Klees, TM | 1 |
| Nakken, KO | 1 |
| Lossius, R | 1 |
| Johannessen, SI | 1 |
| Briggs, DE | 1 |
| French, JA | 1 |
| Bootsma, HP | 1 |
| Ricker, L | 1 |
| Diepman, L | 1 |
| Gehring, J | 1 |
| Hulsman, J | 1 |
| Lambrechts, D | 1 |
| Leenen, L | 1 |
| Majoie, M | 1 |
| Schellekens, A | 1 |
| de Krom, M | 1 |
| Aldenkamp, AP | 1 |
| Plattner, B | 1 |
| Pahs, G | 1 |
| Kindler, J | 1 |
| Williams, RP | 1 |
| Hall, RE | 1 |
| Mayer, H | 1 |
| Steiner, H | 1 |
| Feucht, M | 1 |
| Trimble, MR | 1 |
| Sander, JW | 1 |
| Wittenborn, JR | 1 |
| Gualtieri, CT | 1 |
| Golden, RN | 1 |
| Fahs, JJ | 1 |
| Chouinard, G | 1 |
| Annable, L | 1 |
| Ross-Chouinard, A | 1 |
| Olivier, M | 1 |
| Fontaine, F | 1 |
| Oswald, WD | 1 |
| Matejcek, M | 1 |
| Lukaschek, K | 1 |
| Dennler, HJ | 1 |
| Oswald, B | 1 |
| Neznamov, GG | 1 |
| Siuniakov, SA | 1 |
| Davydova, IA | 1 |
| Teleshova, ES | 1 |
| Lapin, I | 1 |
| Kossoff, EH | 1 |
| Bergey, GK | 1 |
| Freeman, JM | 1 |
| Vining, EP | 1 |
| Petrie, WM | 1 |
| Ban, TA | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Pryce, IG | 1 |
| Yonchev, V | 1 |
| Mashonova, T | 1 |
| Mashonov, N | 1 |
| Nikolkova, S | 1 |
| Mihailov, D | 1 |
| Markov, E | 1 |
| Gallai, V | 1 |
| Mazzotta, G | 1 |
| Del Gatto, F | 1 |
| Montesi, S | 1 |
| Mazzetti, A | 1 |
| Dominici, P | 1 |
| Della Monica, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b[NCT01653262] | Phase 3 | 29 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. A treatment emergent AE is any event that emerges during treatment having been absent pre-treatment, or worsens relative to the pre-treatment state. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | events (Number) |
|---|---|
| Brivaracetam | 67 |
Nonpsychotic behavioral side effects (NBSE) include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Visit 2 (Week 0) to Visit 6 (Week 12)
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 3 |
Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 18 |
A serious adverse event is any untoward medical occurrences in a subject administered study treatment, whether or not the event is related to treatment, with at least one of the follow outcomes: death, life-threatening, initial inpatient hospitalization or prolongation of hospitalization, significant or persistent disability/incapacity, congenital anomaly/birth defect, or an important medical event that may jeopardize the subject and require a medical/surgical intervention. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | events (Number) |
|---|---|
| Brivaracetam | 1 |
"The POS frequency is standardized to a 28-day duration and changes in POS frequency are measured relative to the reported seizure counts for the 4 weeks prior to Visit 2 (Week 0).~Partial seizures can be classified into one of the following three groups:~Simple partial seizures (IA)~Complex partial seizures (IB)~Partial seizures evolving to secondarily generalized seizures (IC)" (NCT01653262)
Timeframe: From 4 weeks prior to Visit 2 (Week 0) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | partial onset seizures (Median) |
|---|---|
| Brivaracetam | 6.0 |
"Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc.~The Investigator completed the assessment by answering the following:~Has there been a clinically meaningful reduction of nonpsychotic behavioral side effects since the start of BRV?~- Yes/No" (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | percentage of subjects (Number) |
|---|---|
| Brivaracetam | 93.1 |
An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) |
|---|---|
| Brivaracetam | 2 |
"There are seven levels for the I-GEBSE:~Marked improvement~Moderate improvement~Slight improvement~No change~Slight worsening~Moderate worsening~Marked worsening" (NCT01653262)
Timeframe: From Study Entry (Visit1, Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Marked improvement | Moderate improvement | Slight improvement | No change | Slight worsening | Moderate worsening | Marked worsening | Missing | |
| Brivaracetam | 10 | 10 | 4 | 2 | 1 | 0 | 1 | 1 |
Nonpsychotic behavioral side effects include (but are not limited to) such symptoms as aggression, agitation, anger, anxiety, apathy, depersonalization, depression, emotional lability, hostility, irritability, etc. (NCT01653262)
Timeframe: From Baseline (maximum of 12 weeks prior to Study Entry at Week -1) to the end of the Treatment Period (Visit 6, Week 12) or Early Discontinuation Visit
| Intervention | subjects (Number) | |||
|---|---|---|---|---|
| Improvement | Unchanged | Worsening | Resolved | |
| Brivaracetam | 8 | 2 | 0 | 19 |
7 reviews available for piracetam and Mental Disorders
| Article | Year |
|---|---|
Safety of Levetiracetam in Paediatrics: A Systematic Review.
Topics: Adolescent; Anticonvulsants; Child; Disorders of Excessive Somnolence; Epilepsy; Humans; Levetiracet | 2016 |
Levetiracetam for managing neurologic and psychiatric disorders.
Topics: Anticonvulsants; Humans; Levetiracetam; Mental Disorders; Nervous System Diseases; Piracetam | 2009 |
Levetiracetam safety profiles and tolerability in epilepsy patients.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Aged; Animals; Anticonvulsants; Astheni | 2004 |
Pharmacotherapy for age-related behavioral deficiencies.
Topics: Adult; Aged; Aging; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Brain; Central | 1981 |
New developments in pediatric psychopharmacology.
Topics: Adolescent; Adult; Aggression; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Autistic Disorder | 1983 |
Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug.
Topics: Animals; Anticonvulsants; Baclofen; Brain; Diazepam; Dopamine Agonists; Dyskinesias; Emotions; GABA | 2001 |
Drugs in geropsychiatry.
Topics: Aged; Anticoagulants; Central Nervous System Agents; Dementia; Dihydroergotoxine; Humans; Hypnotics | 1978 |
6 trials available for piracetam and Mental Disorders
| Article | Year |
|---|---|
An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Mental Disorders; | 2015 |
Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition Disorders; Drug Administration Schedule; Epileps | 2003 |
New developments in pediatric psychopharmacology.
Topics: Adolescent; Adult; Aggression; Anorexia Nervosa; Antidepressive Agents, Tricyclic; Autistic Disorder | 1983 |
Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment.
Topics: Aged; Basal Ganglia Diseases; Behavior; Clinical Trials as Topic; Double-Blind Method; Female; Hemat | 1983 |
[On the meaning of psychometrically operationalized therapeutic effects in the treatment of brain insufficiency phenomena caused by old age demonstrated by the "Nürnberger-Alters-Inventar" (author's transl)].
Topics: Activities of Daily Living; Aged; Aging; Cognition; Dihydroergotoxine; Electroencephalography; Human | 1982 |
A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
Topics: Aged; Cognition Disorders; Female; Humans; Male; Mental Disorders; Piracetam; Psychometrics; Psychot | 1991 |
18 other studies available for piracetam and Mental Disorders
| Article | Year |
|---|---|
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.
Topics: Animals; Antidepressive Agents; Cognition; Dose-Response Relationship, Drug; Glutamic Acid; Impulsiv | 2021 |
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Cohort Studies; Electroencephalography; Epilepsy; Female; Hu | 2017 |
Psychiatric side effects and antiepileptic drugs: Observations from prospective audits.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Dibenzazepines; Drug-Relate | 2017 |
A Man in His 40s With Headache, Lethargy, and Altered Mental Status.
Topics: Adult; Antineoplastic Agents, Hormonal; Craniotomy; Dexamethasone; DNA Nucleotidylexotransferase; He | 2015 |
Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Resistant Epilepsy; Female; Follow-Up S | 2016 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy.
Topics: Administration, Oral; Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Respon | 2010 |
[Two cases of autoimmune encephalitis with antibodies to N-methyl-D-aspartate receptor in intensive care].
Topics: Adrenal Cortex Hormones; Adult; Anticonvulsants; Autoimmune Diseases of the Nervous System; Critical | 2012 |
Assessing adherence-based quality measures in epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Cohort Studies; Epilepsy; Female; Follow-Up | 2012 |
Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Resistance; Drug Th | 2004 |
Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Co | 2007 |
Juvenile myoclonic epilepsy: a benign disorder? Personality traits and psychiatric symptoms.
Topics: Adolescent; Adult; Anticonvulsants; Child; Ethosuximide; Female; Fructose; Humans; Lamotrigine; Leve | 2007 |
Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.
Topics: Adult; Anticonvulsants; Comorbidity; Diagnostic and Statistical Manual of Mental Disorders; Epilepsy | 2007 |
["Fast" and "slow" components of psychotropic activity of the drugs with nootropic effects].
Topics: Adolescent; Adult; Aged; Female; Flavonoids; Ginkgo biloba; Humans; Male; Memory; Mental Disorders; | 2000 |
Levetiracetam psychosis in children with epilepsy.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child, Preschool; Comorbidity; Drug Administration Sched | 2001 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
Clinical research upon mentally ill subjects who cannot give informed consent.
Topics: Ethics, Medical; Human Experimentation; Humans; Informed Consent; Mental Disorders; Piracetam; Resea | 1978 |
Pyramem--investigation of its effect on mental disorders.
Topics: Adult; Drug Administration Schedule; Female; Humans; Male; Mental Disorders; Middle Aged; Piracetam | 1991 |